Emergent BioSolutions to Participate in Investor Conferences

Rhea-AI Summary

Emergent BioSolutions (NYSE: EBS) announced participation in three major investor conferences in Q1 2022. The 40th Annual J.P. Morgan Healthcare Conference is scheduled for January 10-13, with a presentation on January 10 at 8:15 am PST. Following this, the J.P. Morgan 2022 Global High Yield & Leveraged Finance Conference will occur from February 28 to March 2, with a presentation on February 28 at 2:00 pm EST. Lastly, the Cowen & Co. 42nd Annual Health Care Conference will take place March 7-9, with the presentation details to be updated. Webcasts will be accessible live and for replay on the company’s website.

GAITHERSBURG, Md., Jan. 03, 2022 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that members of the company’s executive management team will participate in the following investor conferences in the first quarter of 2022:

• 40th Annual J.P. Morgan Healthcare Conference
  January 10 to 13, 2022
  Company presentation scheduled on January 10 at 8:15 am PST
  Click for Webcast

• J.P. Morgan 2022 Global High Yield & Leveraged Finance Conference
  February 28 to March 2, 2022
  Company presentation scheduled on February 28 at 2:00 pm EST

• Cowen & Co. 42nd Annual Health Care Conference
  March 7 to 9, 2022
  Presentation date and time will be updated on the Emergent website as the information becomes available
  

For conferences where a presentation is planned, the company’s webcast presentation may include a discussion of the company's recent business developments as well as its financial results and guidance. The webcasts will be available both live, if possible, and by replay, and will be accessible from the Emergent website.

About Emergent BioSolutions
Emergent BioSolutions is a global life sciences company whose mission is to protect and enhance life. Through our specialty products and contract development and manufacturing services, we are dedicated to providing solutions that address public health threats. Through social responsibility, we aim to build healthier and safer communities. We aspire to deliver peace of mind to our patients and customers so they can focus on what’s most important in their lives. In working together, we envision protecting or enhancing 1 billion lives by 2030. For more information, visit our website and follow us on LinkedIn, Twitter, and Instagram.

Investor Contact:
Robert G. Burrows
Vice President, Investor Relations
240-631-3280
burrowsr@ebsi.com

Media Contact:
Matt Hartwig
Senior Director, Media Relations
mediarelations@ebsi.com

FAQ

What conferences is Emergent BioSolutions participating in during Q1 2022?

Emergent BioSolutions will participate in the 40th Annual J.P. Morgan Healthcare Conference, J.P. Morgan 2022 Global High Yield & Leveraged Finance Conference, and Cowen & Co. 42nd Annual Health Care Conference.

When is the Emergent BioSolutions presentation at the J.P. Morgan Healthcare Conference?

Emergent BioSolutions' presentation at the J.P. Morgan Healthcare Conference is scheduled for January 10, 2022, at 8:15 am PST.

What is the date for Emergent BioSolutions' presentation at the J.P. Morgan High Yield Conference?

The presentation at the J.P. Morgan 2022 Global High Yield & Leveraged Finance Conference is on February 28, 2022, at 2:00 pm EST.

Where can I find the webcasts for the Emergent BioSolutions presentations?

Webcasts of the Emergent BioSolutions presentations will be available live and for replay on the company's website.

What is the mission of Emergent BioSolutions?

Emergent BioSolutions aims to protect and enhance life by providing solutions that address public health threats and enhance community health.